A telehealth platform's service coverage is not evidence of a pharmacy's permissions, product basis or fulfilment capacity.
Affected arrangements: Multi-state telehealth teams considering a proposed compounded tirzepatide arrangement.
Identify every participant
Tirzepatide is a dual GIP/GLP-1 receptor agonist. A procurement comparison should name its exact preparation and presentation. Separately identify the telehealth provider, prescriber, compounder, dispensing pharmacy, payment recipient and support owner. A platform brand can conceal multiple facilities and workflows; the buyer needs the actual legal entities behind each step.
Attach the relevant source
FDA's policy page includes a tirzepatide shortage determination dated 19 December 2024 and later compounding-policy material. Treat those dates as historical context, then retrieve the applicable current authority for the arrangement under review. A local availability report or supplier assertion should remain labelled as such rather than being elevated into a regulatory finding.
Work state by state
Make a matrix with the destination state, facility, licence record, product scope, evidence date and outstanding question. A licence check and an allocation commitment answer different questions. Record missing information as unknown; avoid turning unknown into either available or unavailable. Keep any asserted prescribing and dispensing permissions in separate columns for qualified review.
Plan the operational response
Ask who handles rejected prescriptions, delayed orders, temperature concerns, complaints and route changes. Check the notice period, aggregate reporting and data portability needed if the arrangement stops. A continuity plan cannot assume that another preparation or supplier is an automatic substitute. Operations should coordinate review owners and communications while clinical decisions remain with qualified clinicians.
Questions to take forward
- Which facility serves each state?
- What is the documented basis asserted for the preparation?
- Who owns a rejected or delayed order?
Primary sources & evidence limits
FDA: GLP-1 compounding policies and dated shortage milestones ↗Latest dated update retrieved: 1 April 2026 · Accessed 2026-11-17FDA: Concerns with unapproved GLP-1 drugs ↗Publication date not confirmed · Accessed 2026-11-17Texas State Board of Pharmacy: Pharmacy licence search ↗Live register; individual records not checked · Accessed 2026-11-17California State Board of Pharmacy: Licence verification ↗Live register; individual records not checked · Accessed 2026-11-17Primary-source links were opened or retrieved on 17 November 2026. This date records source access, not legal or clinical review. Procurement checklists and commercial models are editorial methods. No live supplier, licence, coverage or capacity verification has been performed.